Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The respiratory syncytial virus attachment glycoprotein (G protein) is a heavily glycosylated 95 kDa viral surface protein essential for RSV pathogenesis and infectivity. As the primary attachment protein of RSV, the G protein binds to host cell receptors including heparan sulfate proteoglycans and other molecules on the surface of ciliated airway epithelial cells, initiating the early stages of viral infection. Unlike the highly conserved fusion (F) protein, the RSV G protein is remarkably variable between viral isolates, with extensive sequence divergence in its mucin-like domains that makes it a useful marker for studying viral evolution and distinguishing between RSV A and B subtypes. Beyond its role in viral attachment, the G protein actively modulates host immune responses and promotes viral evasion of the innate immune system, contributing significantly to disease pathogenesis. Both the G and F glycoproteins are major targets for neutralizing antibodies following natural infection, making them attractive candidates for vaccine development. The G protein's antigenic properties and its critical role in the infection process make it an important target for therapeutic interventions, though its high variability presents challenges for the development of broadly effective treatments across different RSV strains.
The G protein functions through the following mechanism: 1. Recognition and binding: The G protein recognizes and binds to specific receptors on the host cell surface, including heparan sulfate proteoglycans 2. Attachment initiation: G initiates virion attachment to the host cell 3. Immune evasion: The G protein actively evades host immune responses through antigenic variation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Respiratory syncytial virus attachment glycoprotein (G protein) (RSV G protein).